基本信息
views: 383
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Farokhzad and his team of scientists have developed a myriad of nanotechnologies for medical applications. He has authored more than 190 papers (>89,000 citations; H-Index 125) and is an inventor of more than 250 issued / pending patents worldwide.
Dr. Farokhzad was inducted as Fellow in the National Academy of Inventors in 2018, and the College of the Fellows of the American Institute of Medical and biological Engineering in 2012. He was a recipient of the 2023 Mustafa Prize and the 2013 RUSNANOPRIZE, for the development and industrialization of nanoparticle technologies for medical applications. In 2014, he received the Golden Door Award from the International Institute of New England for his societal and economic impact as a naturalized USA citizen. In 2015, he was named as one of The Worldview 100 by Scientific American, which recognized visionaries who shape biotechnology around the world. In 2016, he was among the recipients of the Ellis Island Medal of Honor for his scientific, societal and economic contributions to America as an immigrant. He was selected by Thomson Reuters (Clarivate) among the Highly Cited Researchers in every year from 2014 to 2023. The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. He has previously served on numerous editorial boards including as Associate Editor of ACS Nano (impact factor ~14).
The technologies that Dr. Farokhzad and colleagues have developed formed the basis for the launch of 4 biotechnology companies: BIND Therapeutics (clinical stage public company acquired by Pfizer), Selecta Biosciences (clinical stage public company), PrognomiQ (clinical stage private company) and Seer (commercial stage public company). These companies are translating the aforementioned innovations toward commercialization and societal impact. Dr. Farokhzad has served in various capacities on the Executive team, Board of Directors, and the Scientific Advisory Board of these companies.
Dr. Farokhzad was inducted as Fellow in the National Academy of Inventors in 2018, and the College of the Fellows of the American Institute of Medical and biological Engineering in 2012. He was a recipient of the 2023 Mustafa Prize and the 2013 RUSNANOPRIZE, for the development and industrialization of nanoparticle technologies for medical applications. In 2014, he received the Golden Door Award from the International Institute of New England for his societal and economic impact as a naturalized USA citizen. In 2015, he was named as one of The Worldview 100 by Scientific American, which recognized visionaries who shape biotechnology around the world. In 2016, he was among the recipients of the Ellis Island Medal of Honor for his scientific, societal and economic contributions to America as an immigrant. He was selected by Thomson Reuters (Clarivate) among the Highly Cited Researchers in every year from 2014 to 2023. The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. He has previously served on numerous editorial boards including as Associate Editor of ACS Nano (impact factor ~14).
The technologies that Dr. Farokhzad and colleagues have developed formed the basis for the launch of 4 biotechnology companies: BIND Therapeutics (clinical stage public company acquired by Pfizer), Selecta Biosciences (clinical stage public company), PrognomiQ (clinical stage private company) and Seer (commercial stage public company). These companies are translating the aforementioned innovations toward commercialization and societal impact. Dr. Farokhzad has served in various capacities on the Executive team, Board of Directors, and the Scientific Advisory Board of these companies.
Research Interests
Papers共 354 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Biomaterials (2023): 121951-121951
PLOS ONEno. 3 (2023)
EUROPEAN JOURNAL OF HUMAN GENETICS (2023): 581-581
Cited0Views0Bibtex
0
0
bioRxiv (Cold Spring Harbor Laboratory) (2023)
bioRxiv (2022)
Cited0Views0Bibtex
0
0
Cancer Researchno. 12_Supplement (2022): 6340-6340
CANCER RESEARCHno. 12 (2022)
Cited0Views0Bibtex
0
0
Nature Biomedical Engineeringno. 1 (2022): 72-84
Load More
Author Statistics
#Papers: 353
#Citation: 85474
H-Index: 119
G-Index: 286
Sociability: 7
Diversity: 3
Activity: 133
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn